Levetiracetam
Product Images NDC 24689-106

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 24689-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apnar Pharma Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Clcr Calculation (Clcr Calculation)

Clcr Calculation (Clcr Calculation)
This text appears to be describing a formula to calculate the Creatinine Clearance rate (CLcr) in patients. The formula involves using the patient's age, weight, and serum creatinine levels. The text also mentions that the CLcr is adjusted for body surface area (BSA) using another formula given below. However, there seems to be some errors and non-English characters in the text which makes it difficult to interpret accurately.*
FDA Label Image

Figure 1- Responder Rate In Study 1 (Figure 1 Responder Rate In Study 1)

Figure 1- Responder Rate In Study 1 (Figure 1 Responder Rate In Study 1)
The figure 1 represents the responder rate of patients in Study 1, with a 50% reduction from baseline. The graph shows a range of percentages from 5% to 40%, with the highest percentage belonging to the group who received Levetiracetam at a dose of 3000 mg per day. This group had a significant statistical difference compared to the placebo group.*
FDA Label Image

Figure 2- Responder Rate In Study 2-period A (Figure 2 Responder Rate In Study 2 Period A)

Figure 2- Responder Rate In Study 2-period A (Figure 2 Responder Rate In Study 2 Period A)
The text describes Figure 2 from a Study (Study 2) which indicates a Responder Rate of 250% reduction from the baseline in Period A. The figure also shows statistical significance as compared to placebo.*
FDA Label Image

Figure 3- Responder Rate In Study 3 (Figure 3 Responder Rate In Study 3)

Figure 3- Responder Rate In Study 3 (Figure 3 Responder Rate In Study 3)
The image shows the Responder Rate (-50% Reduction from Baseline) in Study 3, where the percentage of responders in the placebo group taking Levstracetam 3000 mg/day was statistically significant. The graph displays percentages ranging from 0.4% to 15%.*
FDA Label Image

Figure 4- Responder Rate In Study 4 (Figure 4 Responder Rate In Study 4)

Figure 4- Responder Rate In Study 4 (Figure 4 Responder Rate In Study 4)
The figure shows the responder rate of patients in Study 4 who experienced a 50% reduction from their baseline. The percentage of responders in the placebo group was 6%, while the levetiracetam group had 19.6% of responders. The difference was statistically significant. There were 40 patients in this study.*
FDA Label Image

Figure 5- Responder Rate For All Patients Ages In Study 5 (Figure 5 Responder Rate For All Patients Ages In Study 5)

Figure 5- Responder Rate For All Patients Ages In Study 5 (Figure 5 Responder Rate For All Patients Ages In Study 5)
The figure shows the responder rate of all patients between the ages of 1 month and <4 years in Study 5, indicating a 50% reduction from baseline. The two treatments compared are Paceb051 and Levtrssin058, with statistically significant variation observed between the two.*
FDA Label Image

Figure 6- Responder Rate In Pgtc Seizure Frequency Per Week In Study 7 (Figure 6 Responder Rate In Pgtc Seizure Frequency Per Week In Study 7)

Figure 6- Responder Rate In Pgtc Seizure Frequency Per Week In Study 7 (Figure 6 Responder Rate In Pgtc Seizure Frequency Per Week In Study 7)
The text describes a figure that shows the percentage reduction in PGTC seizure frequency per week in Study 7. The figure shows a 250% reduction from the baseline. The text also mentions that the results were statistically significant versus placebo.*
FDA Label Image

Levetiracetam Oral Solution_ Label (Levetiracetam Oral Solution Label)

Levetiracetam Oral Solution_ Label (Levetiracetam Oral Solution Label)
Levetiracetam Oral Solution is a medication that contains 100mg of levetiracetam USP. The usual dosage is provided in the package insert. The medication must be stored in a light-resistant container with a child-resistant closure, and kept out of reach of children. The recommended storage temperature is 25°C (77°F), with excursions allowed between 15-30°C (59°F to 86°F). It comes with a Medication Guide and is manufactured by APNAR PHARMA LP in China, CA, USA. The prescription is for oral use only, and is dispensed in a 473 mL bottle.*
FDA Label Image

Levetiracetam_ Structure (Levetiracetam Structure)

Levetiracetam_ Structure (Levetiracetam Structure)
FDA Label Image

Total Daily Dose For Pediatric Patient (Total Daily Dose For Pediatric Patient)

Total Daily Dose For Pediatric Patient (Total Daily Dose For Pediatric Patient)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.